Abstract Body

Background: New antiretrovirals (ARVs) are needed for treatment-experienced (TE) HIV+ patients due to the development of resistance and the long-term safety and tolerability issues observed with existing agents. BMS-663068 is a prodrug of BMS-626529, an attachment inhibitor that binds directly to HIV-1 gp120, preventing the initial interaction between virus and host cell. This study is investigating the safety, efficacy and dose-response of BMS-663068 versus atazanavir/ritonavir (ATV/r) in TE HIV-1 infected subjects.

Methodology: AI438011 is an ongoing Phase 2b, randomized, active-controlled trial, blinded to BMS-663068 dose. TE adults (≥1 week exposure to ≥1 ARV) with viral loads (VL) ≥1,000 c/mL and susceptibility to all study drugs (BMS-626529 IC50<100 nM) were randomized equally to four BMS-663068 groups (400 or 800 mg, BID; 600 or 1200 mg, QD) and a control group (ATV/r 300/100 mg QD), each with a background of raltegravir (RAL) 400 mg BID + tenofovir disoproxil fumarate (TDF) 300 mg QD. A lead-in monotherapy substudy was performed in approximately 10 subjects per BMS-663068 arm. The primary endpoints were the proportion of subjects with HIV-1 RNA <50 c/mL at Week 24 and the frequency of SAEs and AEs leading to discontinuations through Week 24.

Results: Overall, 254 subjects were randomized and 251 were treated across all arms. The median age was 39 years and 60% were male. The median VL was 4.85 log10 c/mL (43% of subjects had VL > 100,000 c/mL) and the median CD4 count was 230 cells/mm3 (38% had < 200 CD4 cells/mm3). Across all arms, 20-40% had baseline NRTI/NNRTI resistance. Subjects electing to undergo 7 days of BMS-663068 monotherapy (n = 32) showed average VL reductions of 0.7 to 1.5 log10 c/mL at Day 8 (Table). Through Week 24, 69-80% of BMS-663068-treated subjects and 75% of ATV/r-treated subjects had HIV-1 RNA <50 c/mL (Table, modified Intent-To-Treat [mITT] FDA Snapshot). Similarly, 78-87% of subjects in the BMS-663068 arms had HIV-1 RNA <50 c/mL at Week 24 compared with 86% of subjects on ATV/r in the observed analysis (Table). All BMS-663068 doses were well tolerated and no SAEs or AEs leading to discontinuation were related to BMS-663068.

Conclusions: In a TE population, the attachment inhibitor BMS-663068, in combination with RAL and TDF, showed favorable safety and tolerability profiles, with similar efficacy in both mITT and observed analyses in comparison with ATV/r through Week 24. These results support the continued development of BMS-663068.